Brian L. Strom, MD, MPH, executive vice dean for Institutional Affairs at the Perelman School of Medicine at the University of Pennsylvania, has been selected to Chair the Institute of Medicine's (IOM) Committee on the Consequences of Sodium Reduction in Populations.
Strom’s Committee on the Consequences of Sodium Reduction in Populations will work to evaluate the results, study design and methodologies that have been used to assess the relationship between sodium and health outcomes in literature published since the IOM Dietary Reference Intakes report. Of primary interest are the effects (positive and negative) in the population generally, and for population subgroups (particularly those with hypertension, pre-hypertension, chronic heart failure, diabetes, persons 51 years and older, and African Americans).
Dr. Strom's research interests span many areas of clinical epidemiology, but mainly focus on pharmacoepidemiology, the application of epidemiologic methods to the study of drug use and effects. He is best known as a founder of the field of pharmacoepidemiology, and a pioneer in using large automated databases for research.
In addition to his responsibilities as executive vice dean, Strom is also the George S. Pepper Professor of Public Health and Preventive Medicine, professor of Biostatistics and Epidemiology, professor of Medicine, and professor of Pharmacology. Strom previously served as president of the Association of Clinical Research Training and currently is principal investigator (PI) or co-PI for eight National Institutes of Health (NIH)-funded clinical research training programs. Dr. Strom has been a member of the Institute of Medicine since 2001.
Established in 1970, the IOM is the health arm of the National Academy of Sciences, which was chartered under President Abraham Lincoln in 1863. Nearly 150 years later, the National Academy of Sciences has expanded into what is collectively known as the National Academies, which comprises the National Academy of Sciences, the National Academy of Engineering, the National Research Council, and the IOM.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.